SRPT Sarepta Therapeutics Inc.

119.52
-2.5  -2%
Previous Close 122.02
Open 120.57
Price To Book 12.48
Market Cap 7986759540
Shares 66,823,624
Volume 639,227
Short Ratio
Av. Daily Volume 1,127,471

NewsSee all news

  1. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  2. Ghost Tree Capital’s AUM, Returns and Holdings
  3. Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
  4. Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
  5. Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?

SEC filingsSee all SEC filings

  1. 8-K - Current report 181227849
  2. S-8 - Securities to be offered to employees in employee benefit plans 181224120
  3. 8-K - Current report 181174011
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181173974
  5. CT ORDER - Confidential treatment order 181173643

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial ongoing. Mid-2019 regulatory filing expected.
Casimersen (SRP-4045) - ESSENCE
Duchenne muscular dystrophy
Phase 1/2 updated data released October 3, 2018.
Microdystrophin gene therapy
Duchenne muscular dystrophy
Phase 1 trial safety and dosing insight due 1Q 2019.
SRP-5051 - PPMO
Duchenne muscular dystrophy
Rolling NDA to be completed late 2018.
Golodirsen - Exon 53
Duchenne muscular dystrophy
Approved September 19, 2016.
Eteplirsen - Exon 51
Duchenne muscular dystrophy
Phase 1 trial ongoing.
MYO-201
Duchenne muscular dystrophy - LGMD2D
Phase 1/2 complete. Protocol update enabling IV delivery Phase 1/2a trial planned 2018
MYO-102
Duchenne muscular dystrophy - (LGMD2B)
Phase 1/2 biomarker data due 1Q 2019.
MYO-101
Duchenne muscular dystrophy - LGMD2E
Pivotal trial to commence by end of 2018.
LYS-SAF302
Mucopolysaccharidosis type IIIA (MPS IIIA)

Latest News

  1. See what the IHS Markit Score report has to say about Sarepta Therapeutics Inc.
  2. Ghost Tree Capital’s AUM, Returns and Holdings
  3. Analysts Expect Breakeven For Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
  4. Sarepta Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors
  5. Is Sarepta Therapeutics Inc (SRPT) A Good Stock To Buy?
  6. New Research Coverage Highlights Callaway Golf, Synchrony Financial, Roper Technologies, Ringcentral, Sarepta Therapeutics, and Advanced Micro Devices — Consolidated Revenues, Company Growth, and Expectations for 2018
  7. Today's Research Reports on Trending Tickers: Arena Pharmaceuticals and Sarepta Therapeutics
  8. Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  9. How BioMarin Pharmaceutical’s Financials Look in November
  10. Wall Street Analysts Are Mostly Positive on BioMarin
  11. Sarepta Stock More Than Doubles This Year So Far: Here's Why
  12. Today's Research Reports on Trending Tickers: Sarepta Therapeutics and Sage Therapeutics
  13. These Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
  14. Sarepta Therapeutics Announces Pricing of $500,000,000 Public Offering of Common Stock
  15. Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
  16. Hedge Funds Just Stormed Into This Red-Hot Biotech Company

SEC Filings

  1. 8-K - Current report 181227849
  2. S-8 - Securities to be offered to employees in employee benefit plans 181224120
  3. 8-K - Current report 181174011
  4. 424B5 - Prospectus [Rule 424(b)(5)] 181173974
  5. CT ORDER - Confidential treatment order 181173643
  6. 424B5 - Prospectus [Rule 424(b)(5)] 181168008
  7. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181150645
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181150320
  9. 8-K - Current report 181136517
  10. 8-K - Current report 181105967